TITLE

Crunch time for pharma

AUTHOR(S)
Martin, John
PUB. DATE
October 2009
SOURCE
New Scientist;10/10/2009, Vol. 204 Issue 2729, p24
SOURCE TYPE
Periodical
DOC. TYPE
Opinion
ABSTRACT
The author reflects on the implications of financial crises for pharmaceutical research. He says that while big pharmaceutical companies have much money, universities are being starved of resources and research funding has decreased. He asserts that the tax system could at least encourage pharmaceutical companies to invest more wisely. He cites the possible consequence if funds from pharmaceutical companies were combined with a proactive way of recognising patentable inventions and managing university science.
ACCESSION #
44642215

 

Related Articles

  • Look, no strings: publishing industry-funded research.  // CMAJ: Canadian Medical Association Journal;9/18/2001, Vol. 165 Issue 6, p733 

    Editorial. Discusses drug research by pharmaceutical companies. Controversy over research funding; Argument in favor of industry-funded research.

  • Hired Education. Washburn, Jennifer // American Prospect;Feb2005, Vol. 16 Issue 2, p29 

    Discusses the increasing number of universities in the U.S. that look and behave like business enterprises in efforts to become research branches of private industry, as of February 2005. Factors that led to the redefinition of the mission of universities; Significance of publicly funded...

  • Taking after the Tigers. Field, Alan M. // Journal of Commerce (1542-3867);2/13/2006, Vol. 7 Issue 7, p16 

    This article provides information on a new research consortium called the African Biotherapeutics Institute which aims to develop the vast potential of Africa for biodiversity-based, value-added products, including pharmaceuticals and nutritional products. The consortium will bring together...

  • Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands. Schmitz, Arndt A.; Hackethal, Sandra; Schulz, Anke; May, Ekkehard; Steinmeyer, Andreas; Zügel, Ulrich; Asadullah, Khusru // Nature Reviews Drug Discovery;Apr2015, Vol. 14 Issue 4, p294 

    The article discusses a retrospective analysis of internal drug discovery efforts to target the vitamin D receptor (VDR). It relates the donation of compounds from pharmaceutical research groups to academic institutions. It details the results of a survey of 63 recipients who related their...

  • The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases. Coles, L D; Cloyd, J C // Clinical Pharmacology & Therapeutics;Aug2012, Vol. 92 Issue 2, p193 

    There are approximately 7,000 rare disorders, many of which are life-threatening. Diagnosis is often problematic, and therapies are few. Before the passage of the Orphan Drug Act in 1983, neither the pharmaceutical industry nor universities devoted much effort to research on rare diseases....

  • More Funding Needed in Academia.  // Bioworld Week;9/8/2008, Vol. 16 Issue 36, p4 

    The article focuses on the insights of panelists on a workshop on funding translational medicine at the BioPharm America 2009 conference, citing that most drugs on the market are from biotechnology and pharmaceutical companies, though universities have spawned a large amount of research and...

  • Despite financial squeeze, Japan continues drive to globalize its science enterprise. Feder, Toni // Physics Today;Jan2017, Vol. 70 Issue 1, p24 

    The article discusses the initiatives of Japanese government to globalize the science enterprise in Japan. These include the establishment of research centers to do scientific work and inspire reforms in the Japanese academic and administrative cultures, formation of the World Premier...

  • PR View. Herskovitz, Beth // Medical Marketing & Media;Aug2005, Vol. 40 Issue 8, p28 

    Discusses the U.S. Food and Drug Administration's (FDA) monitoring of how drug companies interpret the studies they promote. FDA issuance of warning letters for marketing materials that omit risks or overstate effectiveness; Johnson and Johnson's court victory over Pfizer, which was promoting...

  • Industry sponsored bias in cost effectiveness analyses. John-Baptiste, Ava; Bell, Chaim // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/1/2011, Vol. 342 Issue 7787, p4 

    The authors comment on a study on the association between industry sponsorship and the findings of pharmacoeconomic analyses on single drug treatments, by Garattini and colleagues, published in the "International Journal of Technology Assessment in Health Care." They argue that the overall...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics